Climb Bio, Inc. (CLYM) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Climb Bio, Inc. (CLYM) Earnings Overview
As of June 28, 2026, Climb Bio, Inc. (CLYM) reported trailing twelve-month net income of -$53M, reflecting +42.5% year-over-year growth. The company earned $-0.77 per diluted share over the past four quarters.
Looking at the long-term picture, CLYM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2019.
Climb Bio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), ARQT (-$2M net income, -4.3% margin), DAWN (-$107M net income, -67.8% margin), CLYM has comparable earnings metrics. Compare CLYM vs IMVT →
CLYM Earnings vs Peers
Earnings metrics vs comparable public companies
CLYM Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$60M | +19.0% | -$68M | $-0.88 | - | - |
| 2024 | -$74M | -110.4% | -$82M | $-1.53 | - | - |
| 2023 | -$35M | +22.4% | -$40M | $-1.30 | - | - |
| 2022 | -$45M | +4.7% | -$45M | $-1.72 | - | - |
| 2021 | -$47M | -129.7% | -$36M | $-4.24 | - | - |
| 2020 | -$21M | -215.7% | -$21M | $-1.97 | - | - |
| 2019 | -$7M | - | -$7M | $-0.56 | - | - |
Download Data
Export CLYM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CLYM — Frequently Asked Questions
Quick answers to the most common questions about buying CLYM stock.
What is CLYM earnings per share (EPS)?
CLYM trailing twelve-month (TTM) diluted EPS is $-0.77, reflecting +42.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Climb Bio, Inc.'s net income?
Climb Bio, Inc. (CLYM) trailing twelve-month net income is $-53M as of 2025. Earnings grew +42.5% year-over-year.
Is CLYM profitable?
CLYM is not currently profitable on a TTM basis, reporting a net loss of $-53M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CLYM's earnings growth rate?
CLYM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are CLYM's profit margins?
Climb Bio, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -32.1%.
Is CLYM growing earnings?
Yes, CLYM earnings are accelerating — EPS growth of +42.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-53M. Earnings momentum is strengthening.
What was CLYM's best earnings year?
Climb Bio, Inc.'s highest annual net income on record is $-7M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were CLYM's earnings last quarter?
CLYM's most recent reported quarter was Q1 2026. Net income was $-14M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.